

# Demography and Outcome of Cancer Patients with COVID-19: A Retrospective Cohort Study in Dharmais National Cancer Center Indonesia

Fifi Dwijayanti<sup>1</sup>, Chainurridha Chainurridha<sup>1</sup>, Ahmad Rusdan Handoyo Utomo<sup>2,3</sup>, Mururul Aisyi<sup>1</sup>, Hubertus Hosti Hayuanta<sup>4</sup>, Jaka Pradipta<sup>5</sup>

<sup>1</sup>Research and Development Department, Dharmais Cancer Hospital - National Cancer Center, Jakarta, Indonesia. <sup>2</sup>Dharmais Cancer Hospital - National Cancer Center, Jakarta, Indonesia. <sup>3</sup>Biomedical Science Universitas YARSI, Jakarta, Indonesia. <sup>4</sup>Department of Clinical pathology, Dharmais Cancer Hospital - National Cancer Center, Jakarta, Indonesia. <sup>5</sup>Lung Cancer Research Team, Dharmais Cancer Hospital - National Cancer Center, Jakarta, Indonesia.

## Abstract

**Introduction:** Cancer patients have an increased risk of morbidity and mortality due COVID-19 partly due to their immunocompromised status. We aimed to investigate the associations of clinicopathological factors and survival outcomes in cancer patients with COVID-19. **Methods:** This was a retrospective cohort study comprised of cancer patients treated in Dharmais National Cancer Center, Indonesia. Main inclusion criteria were pathologically confirmed malignancy with positive results of RTPCR COVID-19 tests. **Results:** A total of 16,511 visitors had visited and registered for RTPCR test in Dharmais National Cancer Center from May 2020 to January 2021. Logistic regression showed that male gender (p-value = 0.019; OR = 1.732), haematological type of malignancy (p-value <0.001; OR = 3.073), patients not underwent cancer therapy (p-value = 0.008; OR = 0.485), low RTPCR Ct values (p-value = <0.001; OR = 3.340), poor performance status (p-value = <0.001; OR = 8,194), and disease severity (p-value = <0.001; OR = 5.448) were associated with mortality. **Conclusion:** Overall mortality rate in Dharmais cancer patients (25%) was higher than other cancer patients treated in other hospitals in Asia. Moreover, the mortality rate was similar across all age groups. Poor survival in young age might be explained by the fact that median age of cancer patients was 46 years old. In addition to male gender, cancer patients with low Ct values and having delayed cancer treatment were vulnerable groups of having poor outcomes when diagnosed with COVID-19. Long-term follow-up is required to examine the survival rate in cancer patients with COVID-19.

**Keywords:** COVID-19- Cancer- Survival- Demography- Mortality

*Asian Pac J Cancer Care*, 6 (Suppl 1), 41-49

Submission Date: 10/15/2021    Acceptance Date: 11/16/2021

## Introduction

Currently, the world is struggling with a global pandemic of coronavirus disease 2019 (COVID-19). World Health Organization (WHO) stated it as a pandemic on March 11, 2020 [1]. Globally, there were 190,671,330 confirmed cases of COVID-19, including 4,098,758 deaths, reported to WHO on July 21, 2021 [2]. During this period, Indonesia had recorded more than 1 million positive cases and 76,200 death cases [3].

While worldwide preventive measures have been ongoing, number of new cases continue to rise and pose

persisting threat to all populations, including cancer patients. Patients with cancer had a high risk of contracting severe COVID-19 and with a poorer prognosis than those without cancer [4].

During the pandemic, cancer patients are caught as a unique group with an increased risk of contracting COVID-19 partly due to their immunocompromised condition [4]. Their weakened immunity is resulting from many factors including the malignancy burden and ongoing treatment such as surgery, chemotherapy,

## Corresponding Author:

Dr. Fifi Dwijayanti, SKM, MKM

Research and Development Department, Dharmais Cancer Hospital - National Cancer Center, Jakarta, Indonesia.

Email: fifidwijayanti@gmail.com

radiotherapy, or even due to patients undergoing transplant and use of immunosuppressants [5]. This pandemic has created dilemmas and unpredictable impacts on cancer management which include diagnostic work-ups, treatment schedules, and follow-up visits. The isolation of patients infected with COVID-19 has caused losing valuable clinic visits. New patients could miss an early diagnosis which may lead to worse prognosis. In addition, patients with advanced cancer may have to postpone treatments risking disease progression [6].

Low-and middle-income countries (LMIC) with ailing healthcare systems are more vulnerable to contain the pandemic, especially in efforts to manage cancer patients. Dharmas National Cancer Center in Indonesia has deployed strict mitigation system in order to minimize exposure of viral transmission to healthcare providers and patients to and to optimize cancer management [7]. Our current study analyzed associations of clinical characteristics and outcomes of cancer patients with COVID-19 in Dharmas.

## Materials and Methods

### *Study design and participants*

This was a retrospective cohort study to estimate demographic and clinical factors associated with outcome of cancer patients with COVID-19 in National Cancer Center, Indonesia. COVID-19 incidents were obtained from SARS-CoV-2 reverse transcribed polymerase chain reaction (RT-PCR) test records of patients registered in medical database of Dharmas Cancer Hospital between May 01, 2020 to January 31, 2021. Based on Indonesia's national COVID-19 management guidelines [8], Dharmas conducted confirmatory SARS-CoV-2 RT-PCR test on nasopharyngeal and/or oropharyngeal swabs specimens in the laboratory. Cancer patients were discharged or proceeded to cancer treatment after demonstrating negative test results of two consecutive RT-PCR tests, or being declared free of COVID-19 by pulmonologist-in-charge.

The population in this study were all patients who were treated in and registered at the Dharmas Cancer Hospital. The eligibility criteria were (1) patients with confirmed cancer diagnosis by pathologists or other supporting results in medical records and (2) had positive SARS-CoV-2 RT-PCR-positive tests. Patients with suspected or absent of malignancy were excluded.

### *Data collection and variables*

Data were extracted from hospital medical record of RT-PCR test results. All patients with RT-PCR-positive test results were taken and then evaluated by pathologists to confirm cancer diagnosis. Subsequently, patient demographics (age and gender), clinical characteristics, cancer management, clinical history of COVID-19 treatment, and outcomes were collected. The clinical characteristics included type of malignancy, symptoms, comorbidity, performance status, RT-PCR Cycle Threshold Value (Ct value), and disease severity. We categorized cancer treatment status into treatment naïve and previously

treated patients and type of cancer management (diagnostic biopsy, evaluation, stabilized clinical condition, as well as having targeted therapy, chemotherapy, surgery, radiotherapy, chemoradiation, and others). Lastly, clinical outcome indicated the number of patients who survived or died. Death cases were patients who died of any cause within 30 days of confirmed COVID-19 diagnosis.

Symptoms and comorbidities were collected from patient self-questionnaires. We used The Eastern Cooperative Oncology Group (ECOG) score to measure performance status cancer patients with COVID-19. The ECOG score was ran from 0 to 5, with 0 denoting perfect health and 5 death [9].

This study distinguished in-patients and out-patients to determine the differences in demographic and clinical characteristics of patients between these groups. In-patients indicated that the patient was infected with COVID-19 while undergoing treatment in the hospital wards. On the other hand, outpatients were all patients who had any symptoms of COVID-19, confirmed by RT-PCR who were about to undergo any cancer management modalities. Cancer therapy was divided into two categories i.e. having chemotherapy or no chemotherapy. Surgery, radiotherapy, diagnostics, and treatment for stabilized clinical conditions were included in the non-chemotherapy category.

We also measured COVID-19 disease severity. The Ministry of Health Indonesia classified the disease severity of COVID-19 into four groups, namely asymptomatic or mild, moderate, severe, and critical conditions. Mild symptom is a condition without evidence of viral pneumonia or without hypoxia. Symptoms include fever, cough, fatigue, anorexia, shortness of breath, myalgia. Other non-specific symptoms such as sore throat, nasal congestion, headache, diarrhea, nausea and vomiting, smell (anosmia), or loss of taste (ageusia) [10].

Moderate symptoms in adolescent or adult patients included pneumonia (fever, cough, shortness of breath, rapid breathing) but no signs of severe pneumonia including  $SpO_2 > 93\%$  with room air. In children, it showed symptoms of non-severe pneumonia (coughing or difficulty breathing, rapid breathing, and/or chest wall traction) and no signs of severe pneumonia [10].

In adolescent or adult patients, severe symptoms showed the symptoms of pneumonia (fever, cough, shortness of breath, rapid breathing) and/or respiratory rate  $> 30$  bpm, severe respiratory distress, or  $SpO_2 < 93\%$  in room air. Lastly, critical symptoms comprised of Acute Respiratory Distress Syndrome (ARDS), sepsis, and septic shock [10].

There were two types of PCR assay available at our hospital, namely open system and closed system PCR. Open system PCR in our hospital is using QIASymphony DSP Virus/Pathogen mini kit (Qiagen, Germany) for extraction reagent kit, LightMix Modular SARS-CoV-2 (COVID-19) (Roche, Germany) for amplification reagent kit, and Rotor Gene Q (Qiagen, Germany) for real time PCR cyclers. Target genes for this open system PCR were E and RdRp gene as target genes with CT cut off point 36 and

41 respectively. We used two type of closed system PCR, that are Abbott Real Time SARS-CoV-2 assay (Abbott, USA) and GeneXpert (Cepheid, USA). Abbott Real Time SARS-CoV-2 assay was real time assay performed on Abbott m2000 system for extraction (m2000sp) and amplification (m2000rt). The Abbott assay used RdRP and N genes as target genes with CT cut off point 31.6. GeneXpert used the E and N2 gene targets with CT cut off point 45 each. We used Abbott PCR assay as the main PCR assay. GeneXpert is used for cases requiring fast result (within 2 hours) such as deteriorating patients who require ICU, patients who need immediate medical intervention, or post mortem COVID-19 status determination.

### Statistical analysis

We used descriptive statistics and bivariate analysis. Median and range (min-max) was evaluated for the continuous variables, while the proportion for the categorical variables used to describe the data. We differentiated the proportion of demographics, clinical characters patients in inpatients and outpatients, and death from any cause within 3 months of observation using crosstabulation and chi-square test. Besides, for continuous variables using independent samples t-test. The association independent variables with outcome patient were assessed by logistic regression. All analyses were two-sided and the significance level was set at  $p < 0.05$ .

### Ethical Statement

This study was approved by the Ethical Committee of the Dharmas National Cancer Center (approval No.: 0149/KEPK/X/2020).

## Results

A total of 16,511 visitors had visited and registered for RTPCR test in Dharmas National Cancer Center from May 2020 to January 2021 with the results 878 visitors came positive and 15,633 were negative. There were 403 cancer patients with COVID-19 whereby 170 (42.2%) were inpatients and 233 (57.8%) were outpatients. Patient's demography and clinical characteristics were described, see Table 1. The median age was 46 years; 84.1% of the patients had a solid tumor and breast cancer was the most frequent malignancy. Approximately, half of patients had respiratory symptoms of COVID-19 and near one-fifth of patients had other comorbidities besides malignancy.

The median Ct values of RTPCR positive results were 16.98, Table 2. Most patients were not under chemotherapy program (68.5%). 61% of patients had mild to asymptomatic COVID-19, 59% had ECOG performance score 0-1, and 25% of patients died of any cause.

Male patients were mostly in-patients while female patients were in outpatients. Haematological cancer especially *Acute myeloid leukemia* (AML) had higher proportions of in-patients care than solid tumor. Most common symptoms of in-patients COVID-19 cancer




Figure 1. Outcome of Cancer Patients with COVID-19. Based on Type of Malignancy, Hematological Mortality was Higher than Solid Tumors (A), Lung Cancer and Nasopharyngeal Cancer were the Highest Deaths in Solid Tumors (B), AML was the Highest Mortality in Hematology (C).

patients were respiratory (cough, shortness of breath, fever) and gastrointestinal (nausea, vomiting, and diarrhea). The inpatients disease severity and mortality were also higher than outpatients. Mortality rate in haematological cancer was also higher than solid tumors. Based on type of malignancy, hematological mortality was higher than solid tumors, lung cancer and nasopharyngeal cancer were the highest deaths in solid tumors, AML was the highest mortality in hematology (Figure 1). Chemotherapy was the most frequent modality of cancer management (Figure 2).

Logistic regression showed that gender ( $p$ -value = 0.019; OR = 1.732, 95% CI OR = 1.095-2.739), type malignancy ( $p$ -value =  $<0.001$ ; OR = 3.073, 95% CI OR = 1.761-5.362), Ct value ( $p$ -value =  $<0.001$ ; OR = 3.340, 95% CI OR = 0.192-0.547), performance status ( $p$ -value =  $<0.001$ ; OR = 8,194, 95% CI OR = 4,669-14,381), and disease severity ( $p$ -value =  $<0.001$ ; OR = 5.448, 95% CI OR = 3,916-7,578) were associated with mortality. We did adjustments in therapy cancer and status performance to confirmed the number of deaths in patients with ECOG score  $\leq 2$ . The results showed that mortality in patients who did not undergo chemotherapy was higher than those

Table 1. Demography and Clinical Characteristics of Cancer Patients with COVID-19

Variables	Total (%) (N = 403)	Inpatient (%) (N = 170)	Outpatient (%) (N = 233)
Median Age, (min-max) years	46 (5 - 73)	46 (5 - 73)	48 (7 - 77)
Gender			
Male	148 (36.7)	78 (52.7)	70 (47.3)
Female	225 (63.3)	92 (36.1)	163 (63.9)
Type of malignancy			
Solid tumors	339 (84.1)	124 (36.6)	215 (63.4)
Breast cancer	110 (27.3)	30 (27.3)	80 (72.7)
Lung cancer	28 (6.9)	16 (57.1)	12 (42.9)
Nasopharyngeal cancer	22 (5.5)	9 (40.9)	13 (59.1)
Cervical cancer	28 (6.9)	9 (32.1)	19 (67.9)
Colorectal cancer	36 (8.9)	11 (30.6)	25 (69.4)
Others	112 (27.8)	48 (42.9)	64 (57.1)
Hematology	64 (15.9)	46 (71.9)	18 (28.1)
ALL	13 (3.2)	10 (76.9)	3 (23.1)
Lymphoma	22 (5.5)	10 (45.5)	12 (54.5)
AML	18 (4.5)	15 (83.3)	3 (16.7)
Others	14 (3.5)	12 (85.7)	2 (14.3)
Symptoms			
Asymptomatic	180 (44.7)	15 (8.3)	165 (91.7)
Symptomatic	223 (55.3)	155 (69.5)	68 (30.5)
Respiratory	167 (41.4)	115 (68.9)	52 (31.1)
Gastrointestinal (GI)	12 (3.0)	6 (50.0)	6 (50.0)
Respiratory and GI	36 (8.9)	32 (88.9)	4 (11.1)
Others	8 (2.0)	2 (25.0)	6 (75.0)
Comorbidity			
Malignancy alone	319 (79.2)	136 (42.6)	183 (57.4)
Additional comorbidity			
Hypertension	44 (10.9)	18 (40.9)	26 (59.1)
Heart failure	7 (1.7)	4 (57.1)	3 (42.9)
Diabetes	10 (2.5)	4 (40.0)	6 (60.0)
Multiple comorbidity	23 (5.7)	8 (34.8)	15 (65.2)
Ct value (median, min-max)*	17.17 (2.81 – 31.33)	14.38 (2.81-30.95)	18.00 (3.42-31.33)
Therapy status			
Treatment naïve	168 (41.7)	93 (55.4)	75 (44.6)
Previously treated	74 (18.4)	41 (55.4)	33 (44.6)
Ongoing therapy	161 (40.0)	99 (61.5)	62 (38.5)
Cancer management			
Diagnostic biopsy	58 (14.4)	18 (31.0)	40 (69.0)
Routine Evaluation	36 (8.9)	5 (13.9)	31 (86.1)
Stabilized clinical condition	48 (11.9)	45 (93.8)	3 (6.3)
Targeted therapy	1 (0.2)	1 (100.0)	0 (0.0)
Chemotherapy	122 (30.3)	41 (33.6)	81 (66.4)
Surgery	31 (7.7)	21 (67.7)	10 (32.3)
Radiotherapy	35 (8.7)	12 (34.3)	23 (65.7)
Chemoradiation	6 (1.5)	4 (66.7)	2 (33.3)
Others	66 (16.4)	23 (34.8)	43 (65.2)

Continued Table 1.

Variables	Total (%) (N = 403)	Inpatient (%) (N = 170)	Outpatient (%) (N = 233)
Performance status (ECOG)			
0	103 (25.6)	10 (9.7)	93 (90.3)
1	138 (34.2)	42 (30.4)	96 (69.6)
2	92 (22.8)	57 (62.0)	35 (38.0)
3	48 (11.9)	41 (85.4)	7 (14.6)
4	22 (5.5)	20 (90.9)	2 (9.1)
COVID-19 disease grade			
Asymptomatic	180 (44.7)	15 (8.3)	165 (91.7)
Mild	69 (17.1)	6 (8.7)	63 (91.3)
Moderate	54 (13.4)	52 (96.3)	2 (3.7)
Severe	96 (23.8)	93 (96.9)	3 (3.1)
Critical	4 (1.0)	4 (100.0)	0 (0.0)
Outcomes			
Survive	302 (74.9)	78 (25.8)	224 (74.2)
Deceased	101 (25.1)	92 (91.1)	9 (8.9)

\*based on Abbott Ct value




Figure 2. Cancer Management in COVID-19 Patients. Chemotherapy is the most common cancer management when patients diagnosed with COVID-19.

having chemotherapy, see Table 3.

## Discussion

Given the wide range in disease course for COVID-19, the ability to predict which cancer patients are at particularly high risk of deterioration and negative outcomes would

be of particular value in the clinical setting. Our study found five risk factors that were significantly associated with mortality in cancer patients with COVID-19, i.e. gender, type malignancy, RTPCR Ct values, performance status, and COVID-19 disease severity. Demographic factors and clinical characteristics are important in predicting mortality.

This study investigated the association of age and gender to mortality in cancer patients with COVID-19. The results showed that age was not significant risk factor of mortality and had been showed by previous studies [11,12]. The median age in cancer patients was lower (46 years old) than the general population (50 years old) in Indonesia [13] and over 50 years old in globally [14,15]. In Asia Pacific (China, Singapura, Korea, and Australia) [16-18], Europe (Italy, Spain, France, and United Kingdom) [19-22], and America (USA and Brazil) [23,24] has a median aged more than 60 years [25]. Our data suggest that vulnerability of cancer patients to high risk of mortality was independent of age.

In our cohort, male cancer patients had higher risk of COVID-19 mortality than female patients. Females and males have differences in their susceptibility and response to viral infections, leading to gender differences in the

Table 2. SARS-CoV-2 RTPCR Ct Values Based on Several Assays

Ct value	n	Ct value Cut off	Mean	Median	Min - Max
Abbott*	365	31.6	16.52	17.17	2.81 – 31.33
GeneXpert	8				
E		45	27.4	26.85	16.20 – 42.80
N2		45	30.1	29.4	18.70 – 38.80
Qiagen	20				
E		36	25.48	27.78	10.90 – 33.47
RdRP		41	28.75	31.37	11.49 – 38.63

\*frequently-used



Table 3. Logistic Regression of Cancer Patients with COVID-19 Clinical Outcomes

Variables	Survive (%)	Deceased (%)	Sig	OR	95% CI OR
Age					
< 50	165 (74.7)	56 (25.3)	0.649	0.94	0.721-1.226
50 – 59	79 (74.5)	27 (25.5)			
60 – 69	45 (73.8)	16 (26.2)			
> 70	13 (86.7)	2 (13.3)			
Gender					
Female	201 (78.8)	54 (21.2)	0.019 *	1.732	1.095-2.739
Male	101 (68.2)	47 (31.8)			
Types of malignancy					
Solid tumor	267 (78.8)	72 (21.2)	<0.001 *	3.073	1.761-5.362
Haematology	35 (54.7)	29 (45.3)			
Comorbidity					
No comorbidity	238 (74.6)	81 (25.4)	0.672	1.046	0.850-1.287
Additional comorbidity besides malignancy					
Hypertension	37 (84.1)	7 (15.9)			
Heart failure	3 (42.9)	4 (57.1)			
Diabetes	8 (80.0)	2 (20.0)			
Double comorbidity	16 (69.6)	7 (30.4)			
Therapy status					
Treatment naive	121 (72.0)	47 (28.0)	0.193	0.846	0.659-1.088
Previously treated	55 (74.3)	19 (25.7)			
Ongoing therapy	126 (78.3)	35 (21.7)			
Ct value#					
Abbott (median = 17.17)					
≥ median	159 (86.9)	24 (13.1)	<0.001 *	3.34	1.970-5.664
< median	121 (66.5)	61 (33.5)			
GeneXpert (median = 26.85)					
< median	2 (50.0)	2 (50.0)	0.429	0.5	0.188-1.332
≥ median	0 (0.0)	4 (100.0)			
Qiagen (median = 31.37)					
< median	9 (60.0)	6 (40.0)	0.613	0.375	0.033-4.228
≥ median	4 (80.0)	1 (20.0)			
Performance status					
ECOG ≤ 2	276 (82.9)	57 (17.1)	<0.001 *	8.194	4.669-14.381
ECOG >2	26 (37.1)	44 (62.9)			
ECOG ≤ 2					
not chemotherapy	179 (80.3)	44 (19.7)	0.074	0.545	0.280-1.061
chemotherapy	97 (88.2)	13 (11.8)			
Disease severity					
Asymptomatic	174 (96.7)	6 (3.3)	<0.001 *	5.448	3.916-7.578
Mild	66 (95.7)	3 (4.3)			
Moderate	39 (72.2)	15 (27.8)			
Severe	23 (24.0)	73 (76.0)			
Critical	0 (0.0)	4 (100.0)			

#based on Abbott; \* Significance < 0.05; OR, Odds Ratio

incidence and severity of the disease [26]. However, and likely in association with differences in the incidence of poor condition, risky and preventive behaviours, or immune systems, male gender was overrepresented among

COVID-19 fatalities. This observation was consistent with recent data from China, Spain, and Italy regarding the COVID-19 outbreak showed that the percentage of males who have died due to the infection was much higher than

females [27]. In China, for example, found that the fatality rate among men with the virus was about 65% higher than among women. A study in 177 countries and territories suggested that more consideration should be paid to male patients, particularly those over 65 years old for enhanced clinical management [25].

Cancer patients are particularly susceptible to respiratory pathogens and severe pneumonia, because they are at an immunosuppressive state due to malignancy and anticancer therapy. Nearly half of haematology malignancy had high death rates in this study. One of the reasons why outcomes may be worse in patients with haematologic malignancies is that in many cases, immune responses to the virus are less pronounced and highly variable compared with people with other types of cancer, with delayed or negligible seroconversion, prolonged viral shedding, and sustained immune dysregulation [28]. Lower respiratory tract diseases caused by human coronaviruses in patients with haematological malignancies have been associated with high rates of oxygen use and mortality [29]. Solid tumor on the other hand had good prognoses. More than half solid tumor patients survived from COVID-19.

Cancer management such as chemotherapy, surgery, and radiotherapy protocols may suppress immune system, which may lead to worsening of COVID-19 associated morbidity and/or mortality [30]. Furthermore, cancer patients who were being diagnosed with COVID-19 may also risk cancer progression which may jeopardize a chance of survival [31]. However, there was no strong association between status of cancer therapy and mortality within this study cohort.

Cancer therapy can cause a weakened immune system, including chemotherapy. The first objective of using chemotherapy is to kill cancer cells. Chemotherapy can also affect immune cells and thus contribute not only to effective tumor response but also to tumor resistance [32]. Chemotherapy can cause neutropenia (decreased number of neutrophils, a type of white blood cell). This means the body may not be able to fight infection properly. While chemotherapy may affect survival of blood cancer patients with COVID, others studies show that chemotherapy may not imposed additional survival risk [33,34].

Cancer patients with COVID-19 had delayed treatment because they have to be quarantined for approximately 14 days or more. Delayed treatment of cancer can make adverse consequences on outcome. A four-week delay in treatment was associated with an increased risk of death. For surgery, 6-8% increased risk of death for every four-week delay. This effect was even more marked in some radiotherapy and systemic indications, with an increased risk of death of 9% and 13% for definitive head and neck radiotherapy and adjuvant systemic treatment for colorectal cancer, respectively [35]. Therefore, our data may indicate that the increased rate of mortality in patients who did not undergo chemotherapy may die due to malignancy instead of COVID-19. At this stage we could not distinguish the death of COVID-19 or of malignancy.

The cycle threshold (Ct) value is the number of cycles of amplification to detect the virus genetic

materials. It is an estimate of how much virus was likely in the sample to start with – instead of the actual number of viable virus particles. If the virus is found in a low number of cycles (Ct value under 30), it means that the virus was easier to find in sample and that the sample started out with a large amount of the virus [36]. Clinical knowledge of COVID-19 is constantly evolving, with studies being published at a high rate; however, there is currently only limited data relating to the correlation of viral loads with patient prognoses, such as mortality or disease progression. A study reported on the association between mortality and SARS-CoV-2 Ct value and showed that lower Ct values correlated with increased risk of death, [37] which is consistent with data for previous epidemic-causing coronaviruses [38,39].

Many studies reported on the correlation of Ct values with symptom severity that indicated that lower Ct values were associated with more severe disease. This is consistent with some previous studies of Ct values in other respiratory infections, although other studies do not show correlation [40]. The limitation of our study, we did not perform quantitative measurement of viral particles in laboratory culture and correlate with Ct values.

Lastly, patients with ECOG > 2 had 8 times risk for death. We did an adjustment and the data showed in this category the patients were doing 'not chemotherapy' category and stabilized the clinical condition. In Dharmais Hospital as a tertiary hospital. So, the patients that came to us more likely had poor prognostic. For the patient that came for diagnostic, the moment they got COVID-19, we had to delayed any action or treatment for the cancer.

In conclusion, when exposed to COVID-19, cancer patients had higher mortality rate than general population. Gender as demographics factors has association with mortality significantly. Clinical characteristics such as type malignancy, Ct value, performance status, and disease severity were associated with mortality. COVID-19 had a huge impact on cancer treatment and management. Cancer patients with COVID-19 would postpone doctor visits, diagnostic work-up, chemotherapy, and others which can increase the risk of mortality. Further research is required to investigate the others factor of infection COVID-19 such as body mass index (BMI), blood type, smoking history and examine the survival rate in cancer patients with COVID-19.

## Acknowledgments

We would like to thank all the COVID-19 mitigation team in Dharmais National Cancer Center, Jakarta, Indonesia.

## Conflict Of Interest

The authors report no conflict of interest

## References

1. World Health Organization. Coronavirus disease (COVID-19) pandemic [Internet]. Coronavirus disease. 2020 [cited 2021 July 21]. Available from: <https://www.who.int/emergencies/>

- diseases/novel-coronavirus-2019.
- World Health Organization. WHO Coronavirus (COVID-19) [Internet]. Coronavirus disease. 2021 [cited 2021 July 21]. Available from: <https://covid-19.who.int/>.
  - Satuan Tugas COVID-19. Data Sebaran Situasi virus COVID-19 [Internet]. 2020 [cited 2021 July 21]. Available from: <https://www.covid-19.go.id/:1-5>.
  - Y X, R J, J Z, W L, H S. Risk of COVID-19 for patients with cancer. *The Lancet. Oncology*. 2020 04;21(4). [https://doi.org/10.1016/S1470-2045\(20\)30150-9](https://doi.org/10.1016/S1470-2045(20)30150-9)
  - Jazich A, Alenazi TH, Alhejazi A, Al Safi F, Al Olayan A. Outcome of Oncology Patients Infected With Coronavirus. *JCO global oncology*. 2020 03;6:471-475. <https://doi.org/10.1200/GO.20.00064>
  - Wang Z, Wang J, He J. Active and Effective Measures for the Care of Patients With Cancer During the COVID-19 Spread in China. *JAMA oncology*. 2020 05 01;6(5):631-632. <https://doi.org/10.1001/jamaoncol.2020.1198>
  - Dwijayanti F, Setiadi H, Makful M. COVID-19 and Cancer Care in Indonesia: What we have done in Dharmais Cancer Center Hospital. *Indonesian Journal of Cancer*. 2020 07 01;14:37. <https://doi.org/10.33371/ijoc.v14i2.747>
  - Ministry of Health. Guidelines for the prevention and control of coronavirus disease COVID-19. 4th edition. Jakarta: Ministry of Health Indonesia; 2020:1-35.
  - Oken M, Creech R, Davis T. Toxicology and response criteria of the Eastern Cooperative Oncology Group. *American Journal of Clinical Oncology: Cancer Clinical Trials*. 1982;5:649-55.
  - Burhan E, Susanto A, Nasution S, Ginanjar E, Pitoyo C, Susilo A, et al. Guidelines of COVID-19 Management. Third edit. Jakarta: Ministry of Health Indonesia. 2020;3-6:88-9.
  - Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. *The Aging Male: The Official Journal of the International Society for the Study of the Aging Male*. 2020 Dec;23(5):1416-1424. <https://doi.org/10.1080/13685538.2020.1774748>
  - Zarifkar P, Kamath A, Robinson C, Morgulchik N, Shah SFH, Cheng TKM, Dominic C, Fehintola AO, Bhalla G, Ahillan T, Mourgue d'Algue L, Lee J, Pareek A, Carey M, Hughes DJ, Miller M, Woodcock VK, Shrotri M. Clinical Characteristics and Outcomes in Patients with COVID-19 and Cancer: a Systematic Review and Meta-analysis. *Clinical Oncology (Royal College of Radiologists (Great Britain))*. 2021 03;33(3):e180-e191. <https://doi.org/10.1016/j.clon.2020.11.006>
  - Surendra H, Elyazar IR, Djaafara BA, Ekawati LL, Saraswati K, Adrian V, Widyastuti N, Oktavia D, Salama N, Lina RN, Andrianto A, Lestari KD, Burhan E, Shankar AH, Thwaites G, Baird JK, Hamers RL. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. *The Lancet Regional Health. Western Pacific*. 2021 04;9:100108. <https://doi.org/10.1016/j.lanwpc.2021.100108>
  - Abdihamid O, Cai C, Kapesa L, Zeng S. The Landscape of COVID-19 in Cancer Patients: Prevalence, Impacts, and Recommendations. *Cancer Management and Research*. 2020;12:8923-8933. <https://doi.org/10.2147/CMAR.S272008>
  - Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, Xiong W, Yang D, Chen R, Lu F, Lu Y, Liu X, Chen Y, Li X, Li Y, Summah HD, Lin H, Yan J, Zhou M, Lu H, Qu J. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. *American Journal of Respiratory and Critical Care Medicine*. 2020 06 01;201(11):1380-1388. <https://doi.org/10.1164/rccm.202002-0445OC>
  - Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, Xiong Y, Xiong H, Wang C, Chen C, Xiong F, Zhang Y, Peng Y, Ge S, Zhen B, Yu T, Wang L, Wang H, Liu Y, Chen Y, Mei J, Gao X, Li Z, Gan L, He C, Li Z, Shi Y, Qi Y, Yang J, Tenen DG, Chai L, Mucci LA, Santillana M, Cai H. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. *Cancer Discovery*. 2020 06;10(6):783-791. <https://doi.org/10.1158/2159-8290.CD-20-0422>
  - Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet (London, England)*. 2020 02 15;395(10223):507-513. [https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7)
  - O'Reilly GM, G, Mitchell RD, R, Wu J, J, Rajiv P, P, Bannon-Murphy H, H, Amos T, T, et al.. Epidemiology and Clinical Features of Emergency Department Patients with Suspected COVID-19: Initial Results from the COVID-19 Emergency Department Quality Improvement Project (COVED-2) [Internet]. *Emergency Medicine Australasia*. 2020 [cited 2021 May 29]. Available from: <https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/fr/covidwho-603489?lang=en>.
  - Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A, . Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA*. 2020 04 28;323(16):1574-1581. <https://doi.org/10.1001/jama.2020.5394>
  - Fernández-Ruiz M, Andrés A, Loínez C, Delgado JF, López-Medrano F, San Juan R, González E, Polanco N, Folgueira MD, Lalueza A, Lumberras C, Aguado JM. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. *American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2020 07;20(7):1849-1858. <https://doi.org/10.1111/ajt.15929>
  - Grillet F, Behr J, Calame P, Aubry S, Delabrousse E. Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected with Pulmonary CT Angiography. *Radiology*. 2020 09;296(3):E186-E188. <https://doi.org/10.1148/radiol.2020201544>
  - Lovell N, Maddocks M, Etkind SN, Taylor K, Carey I, Vora V, Marsh L, Higginson IJ, Prentice W, Edmonds P, Sleeman KE. Characteristics, Symptom Management, and Outcomes of 101 Patients With COVID-19 Referred for Hospital Palliative Care. *Journal of Pain and Symptom Management*. 2020 07;60(1):e77-e81. <https://doi.org/10.1016/j.jpainsymman.2020.04.015>
  - Duanmu Y, Brown IP, Gibb WR, Singh J, Matheson LW, Blomkalns AL, Govindarajan P. Characteristics of Emergency Department Patients With COVID-19 at a Single Site in Northern California: Clinical Observations and Public Health Implications. *Academic Emergency Medicine: Official Journal of the Society for Academic Emergency Medicine*. 2020 06;27(6):505-509. <https://doi.org/10.1111/acem.14003>
  - Paules CI, Marston HD, Fauci AS. Coronavirus Infections—More Than Just the Common Cold. *JAMA*. 2020 02 25;323(8):707-708. <https://doi.org/10.1001/jama.2020.0757>
  - Hu D, Lou X, Meng N, Li Z, Teng Y, Zou Y, Wang F.



- Influence of age and gender on the epidemic of COVID-19 : Evidence from 177 countries and territories-an exploratory, ecological study. *Wiener Klinische Wochenschrift*. 2021 04;133(7-8):321-330. <https://doi.org/10.1007/s00508-021-01816-z>
26. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. *Biology of Sex Differences*. 2020 05 25;11:29. <https://doi.org/10.1186/s13293-020-00304-9>
  27. Paz C D, Mulle M, Boudet A, Gaddis I. Gender dimension of the COVID-19 pandemic. *Gen Dimens COVID-19 pandemic*. 18(April). 2020;:964-9.
  28. Abdul-Jawad S, Baù L, Alaguthurai T, Molino del Barrio I, Laing AG, Hayday TS, Monin L, Muñoz-Ruiz M, McDonald L, Francos Quijorna I, McKenzie D, Davis R, Lorenc A, Chan JNE, Ryan S, Bugallo-Blanco E, Yorke R, Kamdar S, Fish M, Zlatareva I, Vantourout P, Jennings A, Gee S, Doores K, Bailey K, Hazell S, De Naurois J, Moss C, Russell B, Khan AA, Rowley M, Benjamin R, Enting D, Alrifai D, Wu Y, Zhou Y, Barber P, Ng T, Spicer J, Van Hemelrijck M, Kumar M, Vidler J, Lwin Y, Fields P, Karagiannis SN, Coolen AC, Rigg A, Papa S, Hayday AC, Patten PE, Irshad S. Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. *Cancer Cell*. 2021 02 08;39(2):257-275.e6. <https://doi.org/10.1016/j.ccell.2021.01.001>
  29. Ogimi C, Waghmare AA, Kuypers JM, Xie H, Yeung CC, Leisenring WM, Seo S, Choi S, Jerome KR, Englund JA, Boeckh M. Clinical Significance of Human Coronavirus in Bronchoalveolar Lavage Samples From Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*. 2017 06 01;64(11):1532-1539. <https://doi.org/10.1093/cid/cix160>
  30. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu C, Desai A, Lima Lopes G, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilan MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet (London, England)*. 2020 06 20;395(10241):1907-1918. [https://doi.org/10.1016/S0140-6736\(20\)31187-9](https://doi.org/10.1016/S0140-6736(20)31187-9)
  31. Seth G, Sethi S, Bhattarai S, Saini G, Singh CB, Aneja R. SARS-CoV-2 Infection in Cancer Patients: Effects on Disease Outcomes and Patient Prognosis. *Cancers*. 2020 Nov;12(11):3266. <https://doi.org/10.3390/cancers12113266>
  32. Rébé C, Ghiringhelli F. Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies?. *Future Oncology (London, England)*. 2015 Oct;11(19):2645-2654. <https://doi.org/10.2217/fon.15.198>
  33. Fox TA, Troy-Barnes E, Kirkwood AA, Chan WY, Day JW, Chavda SJ, Kumar EA, David K, Tomkins O, Sanchez E, Scully M, Khwaja A, Lambert J, Singer M, Roddie C, Morris EC, Yong KL, Thomson KJ, Ardeshta KM. Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy. *British Journal of Haematology*. 2020 Oct;191(2):194-206. <https://doi.org/10.1111/bjh.17027>
  34. Lee LY, Cazier J, Angelis V, Arnold R, Bisht V, Campton NA, Chackathayil J, Cheng VW, Curley HM, Fittall MW, Freeman-Mills L, Gennatas S, Goel A, Hartley S, Hughes DJ, Kerr D, Lee AJ, Lee RJ, McGrath SE, Middleton CP, Murugaesu N, Newsom-Davis T, Okines AF, Olsson-Brown AC, Palles C, Pan Y, Pettengell R, Powles T, Protheroe EA, Purshouse K, Sharma-Oates A, Sivakumar S, Smith AJ, Starkey T, Turnbull CD, Várnai C, Yousaf N, Kerr R, Middleton G. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. *Lancet (London, England)*. 2020 06 20;395(10241):1919-1926. [https://doi.org/10.1016/S0140-6736\(20\)31173-9](https://doi.org/10.1016/S0140-6736(20)31173-9)
  35. Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, O'Sullivan DE, Booth CM, Sullivan R, Aggarwal A. Mortality due to cancer treatment delay: systematic review and meta-analysis. *BMJ (Clinical research ed.)*. 2020 Nov 04;371:m4087. <https://doi.org/10.1136/bmj.m4087>
  36. Trunfio M, Venuti F, Alladio F, Longo BM, Burdino E, Cerutti F, Ghisetti V, Bertucci R, Picco C, Bonora S, Di Perri G, Calcagno A. Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. *Viruses*. 2021 02 11;13(2):281. <https://doi.org/10.3390/v13020281>
  37. Huang J, Ran R, Lv Z, Feng L, Ran C, Tong Y, et al. Chronological Changes of Viral Shedding in Adult Inpatients with COVID-19 in Wuhan, China Jing-Tao. *Clin Infect Dis*. 2020;46(May):1-17.
  38. Chu C, Poon LL, Cheng VC, Chan K, Hung IF, Wong MM, Chan K, Leung W, Tang BS, Chan VL, Ng W, Sim T, Ng P, Law K, Tse DM, Peiris JS, Yuen K. Initial viral load and the outcomes of SARS. *CMAJ : Canadian Medical Association Journal*. 2004 Nov 23;171(11):1349-1352. <https://doi.org/10.1503/cmaj.1040398>
  39. Feikin DR, Alraddadi B, Qutub M, Shabouni O, Curns A, Oboho IK, Tomczyk SM, Wolff B, Watson JT, Madani TA. Association of Higher MERS-CoV Virus Load with Severe Disease and Death, Saudi Arabia, 2014. *Emerging Infectious Diseases*. 2015 Nov;21(11):2029-2035. <https://doi.org/10.3201/eid2111.150764>
  40. Feikin DR, Fu W, Park DE, Shi Q, Higdon MM, Baggett HC, Brooks WA, Deloria Knoll M, Hammitt LL, Howie SRC, Kotloff KL, Levine OS, Madhi SA, Scott JAG, Thea DM, Adrian PV, Antonio M, Awori JO, Baillie VL, DeLuca AN, Driscoll AJ, Ebruke BE, Goswami D, Karron RA, Li M, Morpeth SC, Mwaba J, Mwansa J, Prosperi C, Sawatwong P, Sow SO, Tapia MD, Whistler T, Zaman K, Zeger SL, O'Brien KL, Murdoch DR. Is Higher Viral Load in the Upper Respiratory Tract Associated With Severe Pneumonia? Findings From the PERCH Study. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*. 2017 06 15;64 (suppl\_3):S337-S346. <https://doi.org/10.1093/cid/cix148>



This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.